Value of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to 
 by unknown
RESEARCH ARTICLE Open Access
Value of the tuberculin skin testing and of an
interferon-gamma release assay in haemodialysis
patients after exposure to M. tuberculosis
Luis Anibarro1*, Matilde Trigo2, Diana Feijoó3, Mónica Ríos4, Luisa Palomares3, Alberto Pena1, Marta Núñez4,
Carlos Villaverde5 and África González-Fernández6
Abstract
Background: Patients with end-stage renal disease (ESRD) and Mycobacterium tuberculosis infection pose a high risk
of developing active TB disease. It is therefore important to detect latent TB infection (LTBI) to be able to offer
treatment and prevent progression to TB disease. We assessed the value of the tuberculin skin test (TST) and of an
interferon-gamma release assay (QuantiferonW-TB Gold in-Tube, QFT) for diagnosing LTBI in ESRD patients, after
prolonged exposure to a highly contagious TB case in a haemodialysis unit. As a high number of patients
presented erythema without induration in the TST response, this type of reaction was also analysed.
Method: The TST and QFT were simultaneously performed twelve weeks after the last possible exposure to a
bacilliferous TB patient. If the first TST (TST-1) was negative, a second TST (TST-2) was performed 15 days later to
detect a booster response. A comparison was made between the TST responses (including those cases with
erythema without induration) and those for the QFT. The correlation with risk of infection and the concordance
between tests were both analysed.
Results: A total of 52 patients fulfilled the inclusion criteria. Overall, 11 patients (21.2%) had a positive TST response:
3 for TST-1 and 8 for TST-2, and 18 patients (34.6%) showed a positive QFT response (p = 0.065). Erythema without
induration was found in 3 patients at TST-1 and in a further 9 patients at TST-2. The three patients with erythema
without induration in TST-1 had a positive TST-2 response. Concordance between TST and QFT was weak for TST-1
(κ= 0.21); it was moderate for overall TST (κ= 0.49); and it was strong if both induration and erythema (κ= 0.67)
were considered.
Conclusions: In patients with ESRD, erythema without induration in the TST response could potentially be an
indicator of M. tuberculosis infection. The QFT shows better accuracy for LTBI diagnosis than the TST.
Background
Patients with end-stage renal disease (ESRD) have an
increased risk for developing tuberculosis (TB) disease.
It is estimated that once the infection is produced, the
risk for developing active TB is 6 to 25 times higher than
that in the general population [1,2]. It is difficult to diag-
nose TB disease in such cases, as there are frequently
extrapulmonar locations and nonspecific symptoms.
Moreover, they present a high mortality rate [3].
Patients with Mycobacterium tuberculosis infection
after a recent exposure also have an increased risk for
developing TB disease [4,5]. Hence, the risk of TB infec-
tion and disease is even higher in ESRD patients after a
recent exposure to M. tuberculosis [6]. It is therefore
crucial to detect latent TB infection (LTBI) in these
patients and to offer early treatment that can prevent
progression to active TB disease.
The Tuberculin Skin Test (TST) is based on a
delayed-type hypersensitivity response against a purified
protein derivative (PPD) from M. Tuberculosis, and has
for many years been the standard tool for detecting
LTBI. However, the value of this test is limited by its lack
of specificity, due to cross-reactive immune responses
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caused by previous bacille Calmette-Guérin (BCG) vac-
cination, or by infection with non-tuberculous mycobac-
teria [7]. Moreover, TST has shown limited sensitivity
for detecting M. tuberculosis infection in ESRD patients
[8-12].
T-cell Interferon-gamma (IFN-γ) release assays, known
as IGRAs, are emerging as new screening tools for the
detection of M. tuberculosis infection. They incorporate
specific antigens from M. tuberculosis to induce secre-
tion of INF-γ as a marker of immune responses by T-
cells. Such specific antigens are absent in the BCG
strains and in the majority of non-tuberculous mycobac-
teria, avoiding antigenic cross-reactivity. IGRAs also in-
corporate an internal positive control, so that a failure of
response may reflect an underlying anergy [13]. Two
commercial tests are available: the QuantiferonW-TB
Gold In-Tube (QFT) test (Cellestis Ltd, Carnegie, Aus-
tralia), which uses ELISA to detect INF-γ in the culture
supernatants, and the T-SPOTW.TB (Oxford Immunotec,
Abindgdon, UK), which is based on the enzyme-linked
inmunospot (ELISpot) assay.
As there is no gold-standard method for the diagnosis
of LTBI, it is difficult to estimate the value of IGRA (and
TST) for detecting asymptomatic M. tuberculosis infec-
tion. Correlation with the degree of exposure has been
proposed as a surrogate marker of infection. In ESRD
patients, IGRAs have shown a better correlation with
risk factors for M. tuberculosis infection, and their use
has recently been proposed instead of the TST in the
British Thoracic Society Guidelines for prevention and
management of TB infection and disease in patients with
chronic kidney disease [14]. In addition, IGRAs show
better correlation than TST in TB outbreaks in im-
munocompetent populations [15]. However, very few
studies have directly compared the TST with an IGRA
in haemodyalisis patients after a prolonged exposure to
a bacilliferous patient [16,17].
After the notification of the diagnosis of a bacilliferous
pulmonary TB case in a nurse working at a dialysis unit,
we evaluated patients with ESRD who were attending
the dialysis centre, with the TST and an IGRA test
(QFT). The aims of the present study were to compare
the results of an IGRA with those for the TST in
patients with ESRD after a TB outbreak at the dialysis
centre, as well as to identify factors associated with posi-
tive test results. The study also included an 18-month
follow-up of the cohort of patients.
Methods
Description of the outbreak
A 52-year-old nurse working in a renal dialysis unit was
diagnosed with bacilliferous pulmonary TB. Five months
before diagnosis, the worker developed a cough and dys-
phonia. For nine weeks prior to diagnosis, the worker
was off sick and she did not attend the work place.
Therefore, she had no more contact with the patients
attending the dialysis unit. Microscopic examination of
sputum was 4+ positive of acid-fast bacilli, indicating in-
fectiousness, and sputum culture yielded M. tuberculosis
susceptible to all first-line anti-TB medications. The
nurse had been working at the renal dialysis unit on
week-long alternating morning and evening shifts. Each
shift consisted of four hours of contact time with
patients on haemodialysis treatment. The worker was
considered to be infectious 17 weeks before she left her
workplace [4]. All patients who attended the dialysis unit
during this period were considered to be contacts and
were evaluated. Twelve weeks after the last possible ex-
posure to M. tuberculosis, initial screening was under-
taken by simultaneously performing the tuberculin skin
test (TST) and the QFT assay.
Tuberculin skin test
Trained personnel performed the TST according to the
Mantoux method following the standardized protocol:
0.1 mL (2 TU) of purified protein derivative of tubercu-
lin RT 23 (Statens Serum Institute, Copenhagen, Den-
mark) was injected intradermally to the volar surface of
the forearm. The TST results were read after 72 hours,
and the maximum transverse diameter of the induration
was estimated. TST values ≥ 5 mm were judged positive
according to Spanish national guidelines [18]. A two-
step TST was performed: if the first TST (TST-1) was
negative (<5 mm induration), a second TST (TST-2) was
conducted 15 days later to determine the development
of a booster phenomenon. Patients without induration
in the TST response, but with presence of erythema,
were recorded as “erythema without induration”.
Interferon-gamma release assay
Peripheral blood was processed for the IGRA, using the
QuantiFERONW-TB Gold in-Tube Assay (QFT) accord-
ing to the manufacturer’s instructions (Cellestis Ltd, Car-
negie, Australia). One ml of whole blood was added to
each of the three QFT tubes: TB antigen (containing
ESAT-6, CFP-10 and TB7.7 antigens); mitogen positive
control (containing phytohemagglutinin); and a negative
control. Samples were frozen and stored at −70°C until
analysis. The cut-off value for a positive test was
0.35 IU/mL as recommended by the manufacturer.
Blood was collected for QFT immediately before TST-1,
and before the start of the haemodialysis session.
Data analysis
The following data were obtained: gender, age, body
mass index (BMI), laboratory values (haemoglobin, urea,
creatinine, albumin), BCG vaccination status, aetiology
of renal disease, diabetes mellitus, immunosuppressive
Anibarro et al. BMC Infectious Diseases 2012, 12:195 Page 2 of 8
http://www.biomedcentral.com/1471-2334/12/195
therapy, weeks of exposure to the index case, and the
presence of old healed TB in chest radiography. BCG
vaccination status was evaluated by the careful revision
of the BCG scar by an expertise nurse or by the BCG
vaccination certificate.
Follow-up
Patients with either a positive TST or a positive QFT re-
sponse were considered for treatment for LTBI after ac-
tive TB disease was excluded. No cases of active TB
were found during the study period. The possibility of
TB symptoms was carefully monitored throughout the
long-term 18-month follow-up period.
Statistical analyses
Unless otherwise indicated, data are presented as mean ±
standard deviation (SD). Associations between test
results and variables were assessed by Pearson’s χ2-
square test or Fisher’s exact for categorical variables, and
with Student’s t test or Mann-Witney U rank test for
continuous variables. All statistically significant factors
(P<0.05) or clinically relevant factors with a P<0.2 deter-
mined by univariate analysis were included in models of
multivariate logistic regression analysis. Comparison be-
tween test results was performed using the McNemar
test. All reported P values were two-sided. Concordance
between TST and QFT was assessed using the Kappa co-
efficient (κ). Kappa values indicate weak (≤ 0.40), moder-
ate (0.41-0.60), strong (0.61-0.80), or excellent (>0.80)
agreement. The SPSS statistical software for Windows
(SPSS version 15.0; SPSS Inc, Chicago, IL, USA) was
used in the analyses.
Institutional ethical approval was obtained from the
Ethical Committee of Clinical Research (Xunta de Gal-
icia, Spain) and written informed consent was obtained
from the index case.
Results
Characteristics of the contacts
Initially, the contact investigation included 58 patients
with ESRD attending the haemodialysis unit during the
17-week infectious period of the TB index case. One pa-
tient refused to be included in the study, and a previous
positive TST was documented for five other patients,
who were also excluded from further analysis. Hence, a
total of 52 patients were included in the study.
The mean age of these patients was 62 ±16.8 years.
Seven patients (13.5%) had been vaccinated with BCG.
The aetiology of the end-stage renal failure was hyper-
tensive nephrosclerosis (31%), diabetic nephropathy
(19%), others (29%), and unknown (21%). Eight patients
were receiving immunosuppressive therapy. Two
patients recalled previous contact with a TB patient, but
both had had a negative TST result.
Each patient attended the dialysis ward for about
4 hours for three days a week, except for one patient
who had dialysis on a daily basis. A total of 46 patients
(88.5%) had been in contact with the index case for the
whole 17-week infectious period. The control unit
(where the health personnel work) is located at the
centre of the room, so the degree of exposure to the
index case was considered to be almost identical for all
patients. The other 6 patients with a shorter period of
exposure had been in contact with the index case for 4,
6, 11, 12 (two patients) and 13 weeks each.
Other demographic, clinical characteristics and labora-
tory findings are shown in Table 1.
TST and QFT results
TST results
Of the 52 patients who had been in contact with the
index case, 3 (5.8%) had a positive TST result for the first
test (TST-1) (Figure 1). Fifteen days later, the remaining
49 patients had a second TST (TST-2) and the TST-2
was positive in 8 patients (16.3%). Overall, 11 patients
(21.2%) had a final positive TST. In BCG-vaccinated indi-
viduals, the TST was positive in only 1 patient, and this
was detected at TST-2. In the five patients with radio-
graphic findings suggesting possible old healed TB, the
TST was positive in three cases (one at TST-1 and the
other two at TST-2). The induration measurement of
tuberculin reaction was >10 mm in every patient with
a positive result.
Three patients (6.1%) out of 49 with a negative TST-1
only had erythema. The frequency of patients showing
erythema without induration even increased at the
Table 1 Basic demographic characteristics of 52 patients
with end-stage renal disease from a haemodialysis unit,
all contacts of a healthcare worker who had active
pulmonary tuberculosis while working at the dialysis
centre
CHARACTERISTICS STUDY GROUP
Age in years, mean± SD (range) 62 ± 16.8 (24 to 89)
Male gender, n (%) 31 (59.6)
BCG vaccination, yes, n (%) 7 (13.5)
BMI, mean± SD 27.1 ± 5.0
Hemoglobin (mg/dL), mean± SD 11.5 ± 1.4
Albumin level (mg/dL) mean± SD 2.8 ± 0.4
Diabetes mellitus, yes, n (%) 8 (15.4)
Exposure to index case (weeks, %)
17 week 46 (88.5)
< 17 weeks 6 (11.5)
Radiographic evidence of healed TB, n (%) 5 (9.6)
BMI: Body mass index.
Infectiousness of the Index Case was estimated for 17 weeks before last
exposure.
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second TST, with it being observed in 9 out of the 41
patients with a negative TST-2 (22.0%). It is worth not-
ing that for the three patients with erythema but a nega-
tive TST-1, the second TST performed 15 days later was
clearly positive (Table 2).
A positive TST result was not associated with any of
the variables analysed, although the presence of an old
healed TB in chest radiography approached statistical
significance (p = 0.057).
QFT results
The QFT was performed at the same time as the TST-1
in all the 52 patients, and it was positive in 18 cases
(34.6%). No indeterminate results were found. In BCG-
vaccinated individuals, the QFT result was positive in
only one patient, who had both negative TST-1 and
TST-2 results. In the five patients with radiographic
findings suggesting possible old healed TB, QFT was
positive in three cases (all with positive TST results) and
it was negative in the other two patients, who also had a
negative TST result. A positive QFT result was only sig-
nificantly associated with the presence of old healed TB
in chest radiography (p = 0.043).
– Agreement between the TST and QFT results was
found to be weak when taking into account only the
initial TST (κ= 0.21), whereas it was moderate when
both TST results (TST-1 and TST-2) were
considered (κ= 0.49) (Table 3).
– Overall, the QFT was positive in 18 patients (34.6%),
while the TST was positive in 11 patients (21.2%)
(p = 0.065).
Value of erythema without induration in the TST
response
As an unexpectedly high number of patients presented
erythema without any induration in the TST response,
we attempted to verify if erythema alone could be a valu-
able marker for LTBI. Of the 12 patients with erythema
and no induration in the TST, 8 had a positive QFT re-
sult (2 out of 3 cases with a negative TST-1 result and 6
out of 9 cases with a negative TST-2 result). If both
responses (the presence of erythema without induration
or a positive TST result) were considered to be positive
test results, agreement between the QFT and TST
improved to κ= 0.67 (strong agreement), as shown in
Table 4.
Contact follow-up
All contacts with a positive result for either the TST or
the QFT were considered to have LTBI, after active TB
was excluded. Preventive treatment with isoniazid for
9 months was considered for these patients.
Twenty patients (38.5%) were considered to have LTBI
(two on the basis of a positive TST result, nine on the
basis of a positive QFT result, and nine with positive
results for both TST and QFT). Preventive treatment
was started for 11 patients, of which 8 patients com-
pleted the treatment. Isoniazid treatment was stopped in
two patients because of toxicity, and the final patient in
this group died during LTBI treatment, from causes un-
related to either TB or isoniazid toxicity. The remaining
9 patients did not start LTBI treatment: four of them
due to poor basal performance, while five declined to re-
ceive the treatment.
Eighteen months after the outbreak, none of the 20
patients with LTBI developed active TB. Five patients
Figure 1 Results of the Tuberculin Skin Test and of the QuantiferonW-TB Gold in-Tube assay. TST-1: Tuberculin skin test result in the first-
step testing. TST-2: Tuberculin skin test result in the second-step testing (15 days after TST-1). QFT: QuantiferonW-TB Gold in-tube assay.
Table 2 Relationship between the tuberculin skin test
results and erythema
TST (+) TST(−) erythema (+) TST (−) erythema (−)
TST-1 3 3* 46
TST-2 8 9 32
TST-1: Tuberculin skin test result in the first-step testing.
TST-2: Tuberculin skin test result in the second-step testing (15 days after TST-1).
* The three patients with a negative TST-1 result and erythema boosted to a
positive TST-2 result.
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died during the follow-up period (one during LTBI treat-
ment and four patients without treatment). No death
was related to TB.
The remaining 32 patients with negative results for
both QFT and TST were considered to be not infected,
and did not receive LTBI treatment. After the 18-month
follow-up period of close clinical monitoring, no case of
active TB was found among this group. Four patients
died during the follow-up period, none of the deaths
were related to TB.
Discussion
The present study assessed the value of TST and QFT in
haemodialysis patients after prolonged exposure to a
highly contagious pulmonary TB patient. The results
obtained showed three major findings. First, a single
TST has low sensitivity in detecting LTBI and a two-step
strategy must be carried out to gain sensitivity. Second,
erythema alone (without induration) may be a valuable
marker when interpreting TST in haemodialysis patients.
And third, the QFT shows better sensitivity than the
TST in detecting LTBI in haemodialysis patients.
TST has been shown to be unreliable in patients with
advanced chronic kidney disease, and although a positive
test may be useful for LTBI diagnosis, a negative one
cannot be assumed to be a true negative [8,10,11]. Urae-
mia is a well-known risk factor for impaired immune
cellular response [9,19], and this fact is decisive for both
a lower sensitivity of the TST and a higher risk of pro-
gression from LTBI to TB disease [12]. It has been
shown that immune cells can be activated in ESRD
patients, but the functionality of these cells is impaired.
This is especially true for the subpopulation of T helper
1 (TH1) lymphocytes, which are the cells mainly respon-
sible for cellular immunity and delayed hypersensitivity
responses. Moreover, there is a decrease in the number
of B cells in a pro-inflammatory environment (comple-
ment activation, inflammatory cytokines), together with
an imbalance in the ratio of TH1/TH2 lymphocytes [20].
The suppression of the immune TH1 status entails a
higher rate of anergy, eventually leading to lower posi-
tive TST responses compared to the QFT results. Al-
though limited by the absence of a gold-standard
method to confirm LTBI, in our study QFT has shown a
higher response than TST, which approaches statistical
significance.
Two-step testing in TST has been shown to be crucial
for LTBI diagnosis in patients with ESRD, in the absence
of a known recent exposure to a contagious index case
[21,22]. In our study, 8 patients with an initially negative
TST had a second positive TST 15 days later; thereby,
highlighting the importance of the booster effect in ESRD
patients. The booster effect is believed to result from recall
of waned cell-mediated immunity, akin to the anamnestic
response. A first tuberculin test may boost cell-mediated
immunity in patients with otherwise impaired immune re-
sponse, such as patients with ESRD [23]. Several studies
have addressed the booster phenomenon in ESRD patients
Table 4 Agreement between the results of tuberculin skin
testing and presence of erythema with those for the







QFT negative n 29 5 34
% 55.8% 9.6% 65.4%
positive n 3 15 18
% 5.8% 28.8% 34.6%
total n 32 20 52
% 61.5% 38.5% 100`
kappa value 0.67
TST: Tuberculin Skin Test.
QFT: QuantiferonW-TB Gold in-Tube assay.
Table 3 Agreement between the results of tuberculin skin testing with those for the QuantiferonW-TB Gold in-tube
assay
TST-1 Overall TST
negative positive Total negative positive Total
QFT negative n 34 0 34 32 2 34
(%) 65.4% 0% 65.4% 61.5% 3.8% 65.4%
positive n 15 3 18 9 9 18
(%) 28.8% 5.8% 34.6% 17.3% 17.3% 34.6%
Total n 49 3 52 41 11 52
(%) 94.2% 5.8% 100% 78.8% 21.2% 100%
kappa value 0.21 0.49
TST-1: Tuberculin skin test result in the first-step testing.
Overall TST: Tuberculin skin test result after TST-1 and second-step testing (15 days after first testing).
QFT: QuantiferonW-TB Gold in-tube assay.
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without known recent exposure to a TB index case
[21,22,24-26]. Cengiz et al. detected a boosted response in
a second TST, performed seven days after a first TST, in
24.3% of patients on haemodialysis [22]. Similarly, Habes-
glu et al. found the booster phenomenon in 29.7% of
patients undergoing haemodialysis treatment and with no
epidemiologically recognised factors for LTBI [25]. Our
study has addressed the booster response in the context of
a recent exposure to a highly contagious TB index case.
Therefore, it could be difficult to distinguish between a
booster effect from a real conversion after the tuberculin
“window period”. Nevertheless, this is very unlikely, be-
cause both TST and QFT were performed 12 weeks
after the last possible exposure to the Index Case,
which would make very unlikely a conversion attribut-
able to the “window period” [27]. Our findings support
the view that two-step TST must be performed in
patients with ESRD, even in the context of a recent
exposure to M. tuberculosis.
An unexpected finding of our study was the high
number of patients with erythema, but without indur-
ation, in the TST responses. Erythema without indur-
ation is not generally considered in the interpretation of
the TST in most International Guidelines. However,
some Japanese guidelines suggest taking erythema with-
out induration into consideration when the measure-
ment is over 20 mm [28]. In a contact tracing study
carried out with 566 BCG-vaccinated school students in
Japan, the erythema measurement was correlated with
both the induration measurement and the degree of ex-
posure to the index case. These results suggest that ery-
thema (irrespective of the induration response) could
have a significant value in the interpretation of the TST
results. However, in this study, no concomitant IGRA
testing was performed [29]. In our study, joint assess-
ment of induration and erythema has shown better cor-
relation with the QFT results than when only induration
was taken into account in the TST response. All 3
patients with erythema, but with a negative result in the
initial TST-1, developed a positive TST response 15 days
later. Moreover, of the 9 patients with erythema without
induration in the second TST, six (66.7%) had a positive
QFT result. Overall, our results suggest that in patients
with impaired cell-mediated immune response, such as
patients with ESRD, erythema without induration could
be indicative of a weak immune response to M. tubercu-
losis antigens, even though it did not yield skin indur-
ation. Our findings indicate that M. tuberculosis
infection could be considered in patients with ESRD and
with no induration erythema shown in the TST re-
sponse, particularly in situations of high epidemiological
risk of infection. Nevertheless, more studies and a higher
number of patients than those presented in our study
are required to fully verify this statement.
As there is no gold-standard method to confirm diag-
nosis of LTBI, the accuracy of tests for evaluating LTBI
relies on indirect evidence of infection. There is in-
creasing evidence that IGRA results have a better cor-
relation with known risk factors for LTBI than the TST
responses [13]. In addition, several studies have
assessed this issue in patients with chronic kidney dis-
ease, indicating that for these groups of patients, IGRAs
have a greater accuracy than TST in the diagnosis of
LTBI [30-34]. However, only a few studies have com-
pared TST and IGRA results in haemodialysis patients
after a recent exposure to a bacilliferous TB patient
[16,17]. Winthrop et al. found a better correlation with
risk exposure using Quantiferon-TB-GoldW test (an
older generation of QFT) than when using the TST
after exposure to a pulmonary TB patient in a haemo-
dialysis centre [16]. Yet, they found that the rates of
positive results using the TST and the IGRA were not
significantly different, whereas we found a value close
to statistical significance (p = 0.065). The conclusion
derived from the above cited study and from our
current findings (using the new generation of QFT) is
that IGRAs may offer greater accuracy for the diagnosis
of LTBI in ESRD patients, after exposure to an infec-
tious TB patient [14].
Our study has several limitations that require further
comments. First, due to the limited number of patients
included in the study, our results must be interpreted
with caution, and larger series of patients are necessary
to confirm our findings. This is especially true for the
value of erythema, as very few studies have previously
assessed this item. Second, as there is no gold-standard
method for diagnosing true LTBI, it cannot be ruled out
that higher positivity rates for the QFT could include
some false positive results. Nevertheless, there is increas-
ing evidence about the value of an IGRA as a marker for
LTBI, and even as a marker for the risk of progression to
active TB [35]. Finally, only one commercial IGRA
(QFT) has been evaluated in our study. It has been sug-
gested that the other commercially available IGRA (T-
SPOT.TBW) may have an improved sensitivity in patients
with immunodeficiency disorders [36]. There are several
previous studies that have compared different commer-
cially available IGRAs in ESRD patients [30,32,33]. In a
Korean study comparing the performance of TST, QFT
and T-SPOT.TB in patients undergoing haemodialysis,
the positive rates were 23.5%, 45.9% and 60.4% respect-
ively, suggesting a higher sensitivity for the T-SPOT.TB
test. In addition, the frequency of indeterminate results
was higher for the QFT compared with the T-SPOT.TB
test [32]. In contrast, two other studies failed to demon-
strate significantly better sensitivities with the T-SPOT.
TB test than with the QFT: 47% vs. 40%, respectively,
using an older generation of QFT in a Taiwanese study
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[30], or 22% vs. 46%, respectively, in 62 Swiss patients
deemed to have LTBI [33].
Conclusions
Our results indicate that the QFT shows better sensitiv-
ity than the TST in detecting LTBI in haemodialysis
patients, after exposure to M. tuberculosis. Nevertheless,
if the TST is used for detecting LTBI, a single TST result
has low sensitivity and a two-step strategy must be per-
formed to gain sensitivity.
Although the relatively small number of patients
included in the present study limits, to some extent, the
significance of the conclusions, it can still be emphasized
that special care should be taken in patients with ESRD,
who show erythema after the TST, because erythema
alone (without induration) may be a marker of LTBI
when interpreting TST in these patients.
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